Gramicidin S

Gramicidin S adopts a rigid cyclic beta-sheet structure with hydrophobic leucine and valine residues on one face and positively charged ornithine residues on the other. This amphipathicity drives membrane insertion: the cationic face engages anionic bacterial phospholipids electrostatically, while the hydrophobic face inserts into the lipid bilayer. Disruption proceeds through a carpet-model mechanism, leading to rapid membrane permeabilization and loss of transmembrane potential. The symmetry of the molecule allows simultaneous engagement of two membrane lipid molecules.

The D-phenylalanine residues in gramicidin S are critical for the rigid beta-turn conformation that maintains the amphipathic structure. All-L analogs show significantly reduced antimicrobial activity and altered membrane interaction. The D-residues also contribute to proteolytic resistance, extending the half-life of the cyclic peptide in biological environments compared to linear L-peptide analogs with similar sequences.

Gramicidin S was developed under wartime urgency in 1942 and deployed as a topical wound antiseptic for Soviet troops. Its discovery demonstrated that bacteria could produce effective antibiotics targeting bacterial membranes rather than specific bacterial enzymes. The peptide saved lives in World War II despite limited understanding of its mechanism. This historical context makes it a founding member of the peptide antibiotic field alongside penicillin.

Modern SAR studies of gramicidin S have focused on reducing hemolytic activity while maintaining antimicrobial potency. Analogs with modified ornithine substitutions, altered hydrophobic face composition, and incorporated non-natural amino acids have been developed. Some analogs show improved selectivity ratios (MHC/MIC greater than 100) and serve as leads for next-generation cyclic peptide antibiotics against MRSA and MDR Gram-negative bacteria.